Last Thursday, the Centers for Medicare and Medicaid Services (CMS) announced that it would reverse course on anti-amyloid treatments for Alzheimer's patients and cover Leqembi should it receive full approval from the U.S. Food and Drug Administration (FDA). June is Alzheimer's Awareness month.
Leqembi, produced by Biogen and Eisai,...National News
Support for Medicare coverage of the anti-Alzheimer's drug Leqembi is growing on Capitol Hill, but estimates of the drug's cost may prove to be prohibitive for the Medicare program.
Coverage of the drug through the Medicare program would raise costs for the program by $2 billion to $5 billion per year, according to a new study by...National News
As pressure mounts from stakeholders and lawmakers, Eli Lilly, producer of the experimental Alzheimer's antibody drug donanemab, is saying that it expects the Centers for Medicare and Medicaid Services (CMS) to reverse its prohibition of anti-amyloids.
A bipartisan group of nearly half of U.S. state attorneys general sent a letter to...National News
The U.S. Food and Drug Administration (FDA) has approved the drug Leqembi (lecanemab) for the treatment of Alzheimer's disease, but patients will have a difficult time accessing the treatment due to Medicare rules and a hefty price tag.
Leqembi, developed by the Japanese pharmaceutical manufacturer Eisai and its stateside partner...
Over 6 million Americans, including 150,000 Arizonans are currently living with Alzheimer's Disease. As the need for treatment grows, groups like the Alzheimer's Association are asking the government to strengthen its commitment to research and accessibility. But a Congressional report suggests the U.S. Food and Drug Administration (FDA)...
Last Friday, the Centers for Medicare and Medicaid Services (CMS) published a report that reviewed the Medicare Supplementary Medical Insurance (SMI) Trust Fund for 2023 and determined that cost-savings from unexpectedly low Medicare Part B spending in 2022 could be recommended to drive premium cuts for Part B coverage next year.
The...
Following approval by the Food and Drug Administration (FDA) last year, the Centers for Medicare and Medicaid (CMS) proposed last month to cover the Alzheimer’s disease drug Aduhelm only for beneficiaries enrolled in a clinical trial. The proposal has sparked fierce debate among insurance groups, drugmakers, policymakers and the...
Last Monday, the Food and Drug Administration approved a breakthrough new treatment for Alzheimer's disease. The treatment is the first of its kind in decades but many in the scientific community remain skeptical of the new drug's effectiveness.
Aduhelm -- the brand name of aducanumab -- is designed to eliminate clumps of a toxic...
